1188429-06-2

Upstream product

• 1072-95-3 cyclohexylmethyl chloride 
• 1489-97-0 ethyl 1,4-dioxaspiro[4.5]decane-8-carboxylate 
• 1188429-04-0 8-(chloromethyl)-1,4-dioxaspiro[4.5]decane 
• 23521-81-5 (1,4-dioxaspiro[4.5]dec-8-yl)methanol 
• 1188429-11-9 ethyl 2-(1-(benzyloxycarbonylamino)-4-((methylsulfonyloxy)methyl)cyclohexyl)-5-(methylsulfonyloxy)-6-oxo-1,6-dihydropyrimidine-4-carboxylate 
• 1188429-05-1 benzyl 4-(chloromethyl)-1-cyanocyclohexylcarbamate 

Downstream Products

• 1188424-92-1 N'-(2-((2,5-Dibromo-4-fluorobenzyl)carbamoyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-N,N-dimethylethanediamide 
• 1188425-48-0 N'-(2-((3-chloro-4-fluorobenzyl)carbamoyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-N,N-dimethylethanediamide 
• 1188425-49-1 N'-(2-((4-fluoro-3-methylbenzyl)carbamoyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-N,N-dimethylethanediamide 
• 1188425-55-9 N₁-(2-((4-fluoro-3-(trifluoromethyl)benzyl)carbamoyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-N₂,N₂-dimethyloxalamide 
• 1188425-50-4 N'-(2-((2,4-difluorobenzyl)carbamoyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-N,N-dimethylethanediamide 
• 1188425-54-8 N₁-(2-((2-chloro-4-fluorobenzyl)carbamoyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-N₂,N₂-dimethyloxalamide 
• 1188425-56-0 N₁-(2-((4-fluoro-2-methylbenzyl)carbamoyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-N₂,N₂-dimethyloxalamide 
• 1188425-57-1 N₁-(2-((4-fluoro-2-(trifluoromethyl)benzyl)carbamoyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-N₂,N₂-dimethyloxalamide 
• 1188425-46-8 N₁-(2-((4-fluoro-2-(methylcarbamoyl)benzyl)carbamoyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-N₂,N₂-dimethyloxalamide 
• 1188425-53-7 N₁-(2-((4-fluoro-2-(methylsulfonyl)benzyl)carbamoyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-N₂,N₂-dimethyloxalamide 
• 1188425-47-9 N'-(2-((3,4-difluorobenzyl)carbamoyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-N,N-dimethylethanediamide 
• 1380647-08-4 N'-(2-(5-(4-fluorobenzyl)-1,3-oxazol-2-yl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-N,N-dimethylethanediamide 
• 1380647-07-3 N'-(2-(5-(4-fluorobenzyl)-1,3,4-oxadiazol-2-yl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-N,N-dimethylethanediamide 
• 1380647-06-2 N'-(2-(5-(4-fluorobenzyl)-1,3-thiazol-2-yl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-N,N-dimethylethanediamide 

Relevant academic research and scientific papers

Design, synthesis and SAR study of bridged tricyclic pyrimidinone carboxamides as HIV-1 integrase inhibitors

The design, synthesis and structure-activity relationships associated with a series of bridged tricyclic pyrimidinone carboxamides as potent inhibitors of HIV-1 integrase strand transfer are described. Structural modifications to these molecules were made in order to examine the effect on potency towards wild-type and clinically-relevant resistant viruses. The [3.2.2]-bridged tricyclic system was identified as an advantageous chemotype, with representatives exhibiting excellent antiviral activity against both wild-type viruses and the G140S/Q148H resistant virus that arises in response to therapy with raltegravir and elvitegravir.

HIV Integrase Inhibitors

The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.